tradingkey.logo
tradingkey.logo
Search

Neurogene Inc

NGNE
Add to Watchlist
31.250USD
+0.320+1.03%
Close 09-24 16:00(ET)
616.88MMarket Cap
LossP/E TTM

Neurogene Inc (NGNE) Stock Price Target & Forecast

Analyst Rating

Based on 9 analysts giving stock ratings to Neurogene Inc in the past month.

Buy
4 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
80.429USD+160.03%

NGNE Analyst Recommendation Trends

In the current month, NGNE has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NGNE average Analyst price target in the last month is 80.429.

2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
Strong Buy
4
4
4
4
4
3
3
3
Buy
5
5
5
5
5
5
5
3
Hold
0
0
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
0
0
Sell
0
0
0
0
0
0
0
0
Total
9
9
9
9
9
8
8
6

NGNE Analyst Rating for Peer Comparison

Updated: Sep 24, 2026
Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Ratings
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20

Financial Forecasting

Based on analysts' estimates, NGNE EPS is projected to reach -1.332 in FY2026Q3, following reported EPS of -1.529 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.

EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.19
-1.30
-1.42
-1.33
-1.32
Actual
-1.12
-1.39
-1.53
--
--
Surprise
+5.76%
-6.99%
-7.44%
--
--

FAQs

What is Neurogene Inc's price target?

Analysts forecast that Neurogene Inc's price target is USD 80.43, with the highest forecast at USD 166.00 and the lowest forecast at USD 46.00.

How have Neurogene IncNGNE's recent earnings per share performed?

The market expectation was USD -1.53, while Neurogene IncNGNE's earnings per share (EPS) for the previous quarter was USD -1.39. EPS for the next quarter is expected at USD -1.33.

What is the analyst rating for Neurogene Inc?

Based on the ratings of Neurogene Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.